Risk factor assessment for breast cancer in North Cyprus: a comprehensive case-control study of Turkish Cypriot women

doi:10.3906/sag-1709-54

Cited by 2 publications

(9 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Four studies demonstrated adjusted HR as an estimate effect ( 20 , 21 , 27 , 32 ), three studies demonstrated adjusted OR as an estimate effect ( 28 , 29 , 31 ), and one study demonstrated adjusted RR as an estimate effect ( 30 ).…”

Section: Resultsmentioning

confidence: 95%

“…The characteristics of the included studies are listed in Table 1 . Among the eight studies published between 1996 and 2021, three were case-control studies ( 28 , 29 , 31 ), two were prospective cohort studies ( 20 , 30 ) and three were retrospective cohort studies ( 21 , 27 , 32 ). A total of 4,352 genetically susceptible patients with breast cancer were included, of whom 350 women were treated with fertility treatments.…”

Section: Resultsmentioning

confidence: 99%

“…Five studies reported women with breast cancer family history ( 21 , 29 – 32 ), among which one study only described the independent effects of separate fertility drugs such as CC or gonadotropins ( 32 ) and four studies reported the synthetic effects of fertility treatments ( 21 , 29 – 31 ). Three studies reported BRCA mutation carriers ( 20 , 27 , 28 ), among which two studies reported independent effects on women with BRCA1 or BRCA2 mutations ( 27 , 28 ).…”

Section: Resultsmentioning

confidence: 99%

“…Among the eight included studies, one study only described the independent effects of CC or gonadotropins ( 32 ); seven studies were included to compare synthetic effects of fertility treatments in general genetically susceptible populations ( 20 , 21 , 27 – 31 ), of which three studies reported BRCA mutation carriers ( 20 , 27 , 28 ) and four studies reported women with a family history of breast cancer ( 21 , 29 – 31 ). A meta-analysis showed that there was no significant increase in breast cancer risk by fertility treatments in general genetically susceptible population (pooled OR 1.18, 95% CI 0.96–1.45, P =0.11, I 2 = 36.7%), in women with a family history (pooled OR 1.35, 95% CI 0.97–1.89, P =0.08, I 2 = 60.21%), or in women with BRCA mutations (pooled OR 1.02, 95% CI 0.74–1.4, P =0.9, I 2 = 0%) ( Figure 2 ).…”

Section: Resultsmentioning

confidence: 99%

“…Moderate heterogeneity (I 2 = 60.21%) was present in the five included studies concerning women with a family history of breast cancer, of which one study showed a notable increase in breast cancer risk by fertility treatments (OR 2.17, 95% CI 1.17–4.04) ( 31 ). In agreement with the finding from the sensitivity analysis of the family history group that OR was significantly increased after omitting another single study (OR 1.60, 95% CI 1.17–2.18) ( Supplementary Table SIV ) ( 32 ), it was hard to confirm the safety of fertility treatments in women with a family history of breast cancer.…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Association between fertility treatments and breast cancer risk in women with a family history or BRCA mutations: a systematic review and meta-analysis

Liu

Yue²,

Pervaiz³

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

Women with hereditary breast cancer factors are more likely to be infertile and tend to receive fertility treatments. The safety of fertility treatments that contain hormone-related medications for ovarian stimulation has gained wide attention; however, evidence of the safety of fertility treatments is limited. This study aims to assess the association between fertility treatments and the incidence rate of breast cancer in women with a family history of breast cancer or BRCA mutations. A literature search was conducted in PubMed, Cochrane Library, and Embase. Studies concerning the effect of fertility treatments on breast cancer risk in genetically susceptible women were included. The fixed and random effects models were used to estimate the summary effects. Risk Of Bias In Non-randomized Studies - of Interventions instrument was used to assess the risk of bias in the included studies. A total of 5,282 studies were screened. Five cohort studies and three case-control studies were included. Breast cancer risk was not significantly increased by fertility treatments in general genetically susceptible women [pooled odds ratio (OR) 1.18, 95% confidence interval (CI) 0.96–1.45], women with a family history of breast cancer (pooled OR 1.35, 95% CI 0.97–1.89), or women with BRCA mutations (pooled OR 1.02, 95% CI 0.74–1.4). In subgroup analyses, there was no significant increase in breast cancer risk whether in BRCA1 mutation carriers (pooled OR 1.18, 95% CI 0.81–1.72), BRCA2 mutation carriers (pooled OR 0.54, 95% CI 0.09–3.34), or in the women treated with in vitro fertilization (pooled OR 0.75, 95% CI 0.51–1.1), clomiphene citrate (pooled OR 1.07, 95% CI 0.78–1.45) or gonadotropins (pooled OR 1.32, 95% CI 0.8–2.18). This is the first meta-analysis concerning the impact of fertility treatments on breast cancer risk in genetically susceptible women. Despite the finding that fertility treatment did not significantly increase breast cancer risk in genetically susceptible women, large prospective cohorts with more detailed information are required. Further investigations are needed to explore subtypes of breast cancer, genetic background of hormone-related breast cancer, and the association between BRCA mutations and the incidence of hormone receptor-positive breast cancer. Registration numberPROSPERO(CRD42021281336).

show abstract

Section: Resultsmentioning

confidence: 95%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Association between fertility treatments and breast cancer risk in women with a family history or BRCA mutations: a systematic review and meta-analysis

Liu

Yue²,

Pervaiz³

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

Correlation of ERCC5 polymorphisms and linkage disequilibrium associated with overall survival and clinical outcome to chemotherapy in breast cancer

2023

View full text Add to dashboard Cite

PurposeERCC5 is a DNA endonuclease and nucleotide excision repair gene; its mutations lead to a lack of activity by this enzyme, causing oxidative DNA damage. This study aimed to assess the role of four selected single nucleotide polymorphisms (SNPs) in ERCC5 and their linkage disequilibrium associated with survival analysis and clinical outcomes in breast cancer.Patients and methodsFour SNPs (rs751402, rs17655, rs2094258, and rs873601) of the ERCC5 gene were analyzed using the PCR-RFLP technique, followed by sequencing in 430 breast cancer (BC) cases and 430 cancer-free individuals. Statistical analysis was performed using MedCalc 17 and SPSS version 24, while bioinformatic analysis of linkage disequilibrium was performed using Haploview software 4.2.ResultsMultivariate analysis showed that the rs751402 and rs2094258 polymorphisms were significantly associated with an elevated risk of BC (P < 0.001), while the other two SNPs, rs17655 and rs873601, did not show any association (P > 0.001). Survival analysis revealed that rs751402 and rs2094258 had longer overall survival periods (P <0.001) than rs17655 and rs873601. Moreover, rs751402 and rs2094258 also had significantly longer overall survival (log-rank test, P < 0.005) for all three survival functions (positive family history, ER+PR status, and use of contraceptives), while rs17655 and rs873601 did not show any significant association. Only rs873601 showed a strong negative correlation with all the chemotherapeutic groups.ConclusionThe current results suggest that variations in ERCC5 may contribute to BC development and that their genetic anomalies may be associated with cancer risk and may be used as a biomarker of clinical outcome.

show abstract

Risk factor assessment for breast cancer in North Cyprus: a comprehensive case-control study of Turkish Cypriot women

Cited by 2 publications

References 24 publications

Association between fertility treatments and breast cancer risk in women with a family history or BRCA mutations: a systematic review and meta-analysis

Association between fertility treatments and breast cancer risk in women with a family history or BRCA mutations: a systematic review and meta-analysis

Correlation of ERCC5 polymorphisms and linkage disequilibrium associated with overall survival and clinical outcome to chemotherapy in breast cancer

Contact Info

Product

Resources

About